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INTRODUCTION 
Erectile disorder is an inconvenient condition that affects many men and 
reduces their life quality. It causes problems in private life and may finally lead 
the patient to deep depression. Hormonal, local biochemical and structural 
factors of the penis modulate the erectile dysfunction as a neurovascular 
phenomen. [32] 
It is one of the most common forms of male sexual dysfunctions. Approxi-
mately 40% of men over 40 years of age and 1 in 3 men over 70 years of age are 
suffering from the erectile dysfunction. [9] There are many etiologigal factors 
that play a role in the etiopathogenesis of the erectile dysfunction. The risk fac-
tors which may affect erectile mechanisms are age, vascular factors, metabolic 
diseases, neurologic diseases, HIV/AIDS and some drugs. Such drugs, for 
example, are: antiandrogenic, anticholinergic, antidepressants, antihyperten-
sive, major tranquilizers, anxiolytics, and certain medicines/metabolites. [6] 
Sexual dysfunction is associated with depression and antidepressant 
therapy. [12] Roughly 70% of patients with depressive disorders (23–50% of 
men with depression and 33–90% of women) are having problems with sexual 
function: a decline in libido, the erectile dysfunction, ejaculation disorders in 
men and orgasm and menstruation in women. [4] Most antidepressants may 
cause sexual dysfunction as an adverse effect of treatment. [11]  
Psychological and hormonal factors are also important as they participate in 
the erectile function. [2] According to literature sexual dysfunction is a fre-  Erectile dysfunction etiology and hormonal changes  |  195 
quent problem in hypertensive patients [18, 21, 23, 5] and also common in the 
patients with chronic kidney disease. [30] 30% of hypertensive patients have 
problems with erection. Hypertension and the erectile dysfunction are related 
diseases the common base of which an endothelial dysfunction. The disorder 
of endothelium – derived factors may lead to an increase in the vascular 
smooth muscle contraction. Due to high blood pressure or antihypertensive 
treatment, hypertension can cause the erectile dysfunction. [21] Vasodilation 
in response to endothelium – dependent stimuli is inadequate both in the 
systemic vasculature and the penile arteries. Many antihypertensive drugs may 
have a drug specific side – effect, which worsens sexual function. [23] Older 
antihypertensive drugs (diuretics, beta blockers) have harmful effects on the 
erectile function, but newer drugs (nebivolol, angiotensin receptor blockers) 
have neutral or even beneficial effects. Phosphodiesterase (PDE) – 5 inhibitors 
are effective in hypertensive patients and can be safely administered. On has to 
be careful has to be with alpha blockers and coadministration with nitrates is 
also contraindicated. [18] 
As the erectile dysfunction is mainly a vascular condition, it usually comes 
before the cardiovascular event by 3–5 years. Due to association with acute 
coronary syndromes, its early diagnosing gives an opportunity for cardiovascu-
lar risk reduction. [9] High LDL, smoking, hypertension and diabetes are risk 
factors for the coronary heart disease and also for the erectile dysfunction. The 
erectile dysfunction is a usual problem after the coronary artery disease or 
myocardial infarction. [5] Obese patients with dyslipidemia, type 2 diabetes 
mellitus, and/or depression, should be screened for the erectile dysfunction, 
because of associations between the heart disease, the metabolic disease and 
the sexual dysfunction. [24] Obesity is confessedly a significant risk factor for 
the cardiovascular disease, type 2 diabetes, cancer and the erectile dysfunction 
and low serum sex hormone – binding globulin levels in obesity are associated 
with the low serum total testosterone. The body mass index and serum total 
testosterone concentrations are inversely proportional [3] Visceral obesity 
associates with increased inflammatory responses and thereof predisposes the 
endothelial dysfunction which together with androgen deficiency are related to 
the patophysiological mechanisms of the erectile dysfunction. [29] 
The increased arterial inflow and the restricted venous outflow, coordinated 
with corpus cavernosum and penile arterial smooth muscle relaxation, are the 
hemodynamic processes which are related to the penile erection. [16] The 
balance of vascular relaxants and constrictors determines the tone of cavernosal 
smooth muscle cells, which governs the erectile status of the penile tissue. 196  |  H. Orro, K. Kokk 
Vascular relaxants are important in regulating the tone of the cavernosal 
smooth muscle. Adenosine is a short – lived vasorelaxant, which relaxes the 
corpus cavernosum and promotes the penile erection. It works via the cyclic 
nucleotide second messenger signaling to promote smooth muscle relaxation. 
Impaired adenosine signaling through A(2B) receptor [22] is associated with 
the erectile dysfunction. [31] 
 
 
HORMONAL CAUSES OF ERECTILE DYSFUNCTION 
When men are ageing a progressive and small decline in several sex hormones 
takes place. It includes testosterone and dehydroepiandrosterone, and the 
related increases in the luteinizing hormone, the follicle – stimulating hor-
mone, and the sex hormone – binding globulin. [1] 
Changes in the body mass index, osteoporosis, sleep and mood disorders 
are correlated with hormonal changes in the ageing male. [26] 
 Testosterone, which is the major circulating androgen in male, shows an 
age – related decline in the ageing male. [7] The age – related changes in 
reproductive hormones in men are not precipitous as in women. Such gradual 
changes appear throughout many years. The decline in the serum testosterone 
level causes many symptoms of hypogonadism, which include: the loss of 
energy, the decreased libido, the depressed mood, the erectile dysfunction, the 
decreased muscle mass and strength, the increased fat mass, frailty, osteopenia, 
and osteoporosis. This condition is also known as an andropause and diag-
nosed by clinical symptoms and the laboratory-measured serum testosterone 
levels. [15 ] Disorders at the hypothalamic or pituitary level (hypogonado-
tropic forms) or the testicular dysfunction (hypergonadotropic forms) can 
cause hypogonadism. [28] 
A remarkable percentage of men over 60 years of age are having serum 
testosterone levels below the lower limits of young male adults. [27] 
The classification of hypogonadism includes primary, secondary, and mixed 
hypogonadism. The disorders of the testes and therefore low testosterone 
production and impaired fertility cause primary hypogonadism, whereas dis-
orders of the hypothalamus and the pituitary cause secondary hypogonadism 
which shows low testosterone and low or inappropriately normal LH and FSH 
levels. Both defects can cause mixed hypogonadism. Older men usually have 
secondary or mixed hypogonadism. [27] 
Hypogonadism is a condition which may be congenital or acquired. Acqui-
red hypogonadotropic hypogonadism includes the postnatal disorders that   Erectile dysfunction etiology and hormonal changes  |  197 
change or impair the function of gonadotropin – releasing hormone (GnRH) 
neurons and/or pituitary gonadotroph cells. The most usual causes of acquired 
hypogonadotropic hypogonadism are pituitary tumors, particularly prol-
actinoma, pituitary surgery and head trauma, cranial/pituitary radiation 
therapy and also sellar tumors or the cyst of the hypothalamus or infundi-
bulum, infiltrative, vascular, the iron overload and other disorders. [25] 
The luteinizing hormone receptor and the follicle stimulating hormone 
receptor are important factors in female and male reproduction. [19] Luteini-
zing hormone (LH), as follicle – stimulating hormone (FSH) and thyroid – 
stimulating hormone (TSH), is the member of the pituitary glycoprotein 
hormone family and stimulated by gonadotrophin – releasing hormone 
(GnRH). Our study group investigated the LH receptor expression in the 
mouse penis, to see if its effects are possible in the penis. We used immuno-
cytochemistry, western blotting and quantitative reverse transcriptase poly-
merase chain (qRT–PCR) reaction to detect LH receptor in the Balb/c mice 
penis. Positive immunoreaction to LH was found in the mouse penis urethral 
epithelium, in the endothelial cells of the cavernous spaces both in corpus 
spongiosum and corpus cavernosum and also in the testis tissue, which were 
used as positive control and where positive immunoreaction to the LH recep-
tor was detected in the Leydig cells and in the central part of the seminiferous 
tubules next to the lumen. The LH receptor antigen was also present by using 
Western blotting and quantitative RT–PCR. As we managed to show, using 
three methods, that the LH receptor is expressed in the penile tissue of male 
mice, this finding may suggest, that LH can affect the corpus spongiosum and 
corpora cavernosa in mice. [13] 
Hypogonadism is not the only condition that is connected with the male 
sexual dysfunction. Other endocrine disorders also associate with it. Severe 
hyperprolactinemia (>35 ng/mL or 735 mU/L), often related to a pituitary 
tumor, influences the sexual function negatively and impairs sexual desire, 
testosterone production and through it the erectile function. [17] Hyper- and 
hypothyroidism may also influence the male sexual health. Premature ejacu-
lation and maybe also the erectile dysfunction are connected with hyperthyroi-
dism. Sexual desire and the impaired ejaculatory reflex are associated with 
hypothyroidism. [17, 14, 8] The erectile function and sperm parameters are 
disadvantageously affected by hypothyroidism, including the sperm count, 
morphology and motility. Its is recommended to measure thyroid hormones in 
the patients with the erectile dysfunction and sperm abnormalities. [20] 
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SUMMARY 
The erectile dysfunction is a common disorder around the world and it largely 
influences largely the quality of life. 
The individual general health status, the cardiovascular disease, diabetes 
mellitus, some genitourinary disease, psychiatric or psychological disorders and 
overall life conditions are risk factors linked with the sexual dysfunction.  
As mentioned above, the hormonal changes which take place in time and 
some drugs are also associated with erectile disorders.  
While many etiological factors may cause the erectile dysfunction, it is 
important to avoid their development and/or reduce their influence to the 
minimum. It includes preventing atherosclerosis and avoiding diabetes, neuro-
genic disorders or mental distress. The healthy lifestyle which contains physical 
activity together with balanced nutrition, nonsmoking and appropriate alcohol 
consumption is recommendable. [10] 
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